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The aim of this study was to establish the pharmacokinetics of levofloxacin (LVFX) and determine the optimal dose
of this drug in critically ill patients receiving continuous hemodiafiltration (CHDF). The results of in vivo and in vitro
studies showed the pharmacokinetics of LVFX total clearance (CLtotal) according to the creatinine clearance (CLCre),
dialysate flow (QD), and ultrafiltrate flow (QF), to be as follows: CLtotal (l/h) = 0.0836 × CLCre (ml/min) + 0.013 × body
weight (kg) + 0.94(QD + QF) (l/h). The optimal dose of LVFX was expressed by the following formula: 50 × CLtotal.
These results demonstrate that the usual dose of LVFX (500 mg) was sufficient for the patients evaluated in this study.
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The pharmacokinetics of levofloxacin (LVFX) total clear-
ance (CLtotal) were determined based on the creatinine
clearance (CLCre), dialysate flow (QD), and ultrafiltrate
flow (QF), as follows:
CLtotal l=hð Þ ¼ 0:0836 CLCre ml=minð Þ þ 0:013
 bodyweight kgð Þ þ 0:94 QD þQFð Þ
 l=hð Þ
Introduction
Critically ill patients often require continuous hemodia-
filtration (CHDF) as a result of acute kidney injury in-
duced by severe sepsis. Levofloxacin (LVFX) is widely
used for treatment in these patients. However, the
pharmacokinetics (PK) of LVFX during CHDF are not
uniform, as CHDF is performed using various combina-
tions of the dialysate flow (QD) and ultrafiltrate flow
(QF). The aim of the present study was to estimate the
PK of LVFX in patients receiving CHDF and determine
the optimal dose of LVFX for this patient population.* Correspondence: tacchi1112@yahoo.co.jp
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Approval for this study was obtained from the institu-
tional review board, − The Ethics Committee of Hokkaido
University School of Medicine (011–0107). Informed
consent for this study was obtained from the patients’
next of kin.In vitro study
A CHDF circuit model (JUN-600, JUN-KEN MEDICAL
Co., Tokyo, Japan) was established using a cellulose tri-
acetate hollow fiber 1.1 m2 hemofilter (UT-1100, Nipro,
Japan). The machine was primed with fresh frozen
plasma (FFP), and 100 mg of LVFX were added to the
circuit. The FFP flow was fixed at 150 ml/min, and the
CHDF conditions were as follows: the QD was defined
from 0, 1, and 2 l/h; the QF was defined from 0, 1, and 2
l/h, independent of QD. Samples were obtained from the
prehemofilter and ultrafiltrates at 15, 30, 45, and 60 min
after the start of CHDF. The sieving coefficient (SC)
values were calculated based on the LVFX concentra-
tions in the filtrates and prehemofilter. The levels of
clearance (CL) via CHDF (CLCHDF) were obtained for
the product of SC and (QD + QF) and then were plotted,
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Figure 1 Pharmacokinetics of levofloxacin (LVFX) clearance (CL) during
continuous hemodiafiltration. A simple linear regression analysis
revealed a strong correlation between LVFX CLCHDF and QD + QF.
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Four patients with acute kidney injury were administered
LVFX during CHDF (ACH-Σ, Asahi Kasei Medical. Co.,
Tokyo, Japan). The hemofilter used in the in vivo study
was a polysulfone hollow fiber 1.3 m2 hemofilter (EXCEL-
FLO AEF-13, Asahi Kasei Medical. Co., Tokyo, Japan). Re-
placement fluid was connected to the post-filter blood
line. The 24 h creatinine clearance values were accurately
measured based on the urine and serum creatinine levels
and the 24 h urine output. The LVFX dose was set at 500
mg/day for all patients. Blood samples were collected be-
fore the administration of LVFX and at 1, 2, 6, 12, and 24
hours after the start of drug administration. The con-
centration of LVFX was determined according to a
high-performance liquid chromatography method, and
a pharmacokinetic analysis was performed using aTable 1 Characteristics of the patients
Patient Sex Age (years) Diagnosis Weight (kg)
1 Male 75 Ruptured AAA 70.7
2 Male 59 OHCA 88.9
3 Male 46 Congenital
heart disease
50.0
4 Male 58 ML 58.3
Mean ± SE 59.5 ± 6.0 - 70.0 ± 8.5




42 3.4 1.0 2.0 4.0
43 0.9 1.0 2.0 4.0
40 - 1.0 2.0 -
32 3.4 0.5 1.5 2.9
39.3 ± 5.0 2.6 ± 0.8 0.86 + 0.13 1.88 + 0.13 3.6 ± 0.4
AAA abdominal aortic aneurysm, OHCA out-of-hospital cardiac arrest, ML malignant
AKI acute kidney injury, PCAS post-cardiac arrest syndrome, Cre creatinine, ICU inte
CLcre creatinine clearance, CLtotal total clearance, QD dialysate flow, QF ultrafiltrate fnonlinear least-squares regression program. The parame-
ters were calculated by employing a two-compartment
open model with a constant rate of infusion. The area
under the concentration-time curve (AUC) was deter-
mined based on the trapezoidal rule. The optimal dose of
LVFX was calculated based on the following relational
expression:
CLtotal ¼ doseof drug=AUC
Results
The CLCHDF obtained via interpolation into a simple lin-
ear regression of CLCHDF against (QD + QF) closely cor-
related with the experimental data (Figure 1). The PK of
LVFX clearance (CLvivo) was determined based on the
creatinine clearance (CLCre) and body weight (BW), ac-
cording to previous study [1]. The LVFX total clearance
(CLtotal) in a patient receiving CHDF was calculated as
follows:
CLtotal l=hð Þ ¼ CLvivo þ CLCHDF
¼ 0:0836 CLCre ml=minð Þ þ 0:013
 BW kgð Þ þ 0:94 QD þQFð Þ l=hð Þ
The values of predictive CLtotal were calculated based
on this formula. Table 1 shows the characteristics of the
patients. We were unable to calculate the predictive
CLtotal in patient No. 3 because the urine creatinine level
was not examined in this case. The LVFX concentration-
time curve is shown in Figure 2, and the pharmacoki-
netic parameters of LVFX are presented in Table 2. The
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33.8 ± 4.9 - 1.25 + 0.29 38.5 + 12.7
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Figure 2 Pharmacokinetics of the levofloxacin (LVFX) concentration-
time curve during LVFX administration of 500 mg first 24 hours. Cons,
concentration. SE, standard error.
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The ratio of AUC/minimum inhibitory concentration
(MIC) is a well-known important PK and pharmaco-
dynamics predictor of the clinical efficacy of fluoroquino-
lones, including LVFX. Previous studies suggest that the
AUC/MIC of ≥100 (h) is required in compromised pa-
tients or those exhibiting severe Gram-negative rod or
staphylococcal infection [2-4]. In addition, the MIC for
90% of tested strains against most common Gram-negative
aerobic pathogens is < 0.5 (μg/ml) [5]. Therefore, we
determined the target AUC to be ≥ 50 and the optimal
dose of LVFX to be 50 × CLtotal. Hence, the LVFX con-
centrations reached higher than optimal concentra-
tions, and infection could therefore be successfully
controlled in these patients.
Three factors affect the PK during CHDF as follows:
1) pore size and protein binding fraction of the drug; 2)
molecular size; 3) QD and QF in the CHDF protocol [6].
The triacetate and polysulfone membranes used in thisTable 2 Pharmacokinetic parameters of levofloxacin in
the patients receiving continuous hemodiafiltration
Patient CLtotal (l/h) t1/2 (h) Cmax (mcg/ml) AUC [(mg/l) h]
1 4.62 13.1 5.7 108.3
2 12.3 14.4 3.0 40.8
3 6.64 28.9 4.7 75.3
4 7.01 11.4 4.4 71.3
Mean ± SE 7.63 + 1.6 16.9 + 4.0 4.5 + 0.6 73.9 + 13.8
CLtotal total clearance, t1/2 a half-life, Cmax maximum concentration, AUC area
under the concentration-time curve, SE standard error.study have large pores and do not have a capacity for drug
absorption, characteristics recommended for CHDF. The
molecular size of LVFX is 361 Da, which is less than that
of ciprofloxacin (CPFX) (368 Da). The results of our previ-
ous study suggested that the pore size of the hemofilter
does not influence the CLCHDF, likely due to the suffi-
ciently low molecular weight of CPFX [7]. This previous
study also indicated that the surface area of the hemofilter
with a large amount of QD possibly affects the clearance
of small solutes, such as fluoroquinolones [7]. Therefore,
the current results are not applicable in cases in which the
QD is large.
The limitations of this study should be addressed.
First, the results of a study by Takigawara et al. [1],
showing the relationship between the PK of LVFX and
the CLCre, were based on patients with a normal renal
function. These results are not applicable to the present
study, as we included patients with more severe kidney
injury. Second, the current study included a very small
number of patients. Therefore, a larger, more precise
clinical study is needed to confirm our results.
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